A Speedinvest portfolio company

Orakl Oncology

Year Invested
Orakl Oncology leverages a collection of patient tumor avatars to transform drug development in oncology.

Cancer complexity leads to a 96% failure rate of drug candidates in clinical trials and a shortage of new treatments. Orakl Oncology’s ambition is to finally address the heterogeneity of cancer and patient specificities as early as possible in drug development. By creating a collection of avatars of patients’ tumors, they predict how each patient will respond to future drugs. Orakl Oncology is an interdisciplinary techbio platform that combines best-in-class biology with deep clinical data and machine learning to efficiently discover and optimize new treatments for the right patients. Thanks to their technology, Orakl Oncology works with drug developers to bring better drugs to patients, faster.

Hi, we're Speedinvest

Proud partners with Europe's most visionary founders who are redefining technology's role in our daily lives.

Tell us about your startup